218 related articles for article (PubMed ID: 21180528)
1. Causes of, and therapeutic approaches for, proton pump inhibitor-resistant gastroesophageal reflux disease in Asia.
Kinoshita Y; Ishihara S
Therap Adv Gastroenterol; 2008 Nov; 1(3):191-9. PubMed ID: 21180528
[TBL] [Abstract][Full Text] [Related]
2. Current Diagnosis and Management of Suspected Reflux Symptoms Refractory to Proton Pump Inhibitor Therapy.
Richter JE
Gastroenterol Hepatol (N Y); 2014 Sep; 10(9):547-55. PubMed ID: 27551249
[TBL] [Abstract][Full Text] [Related]
3. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
4. The proton pump inhibitor test and the diagnosis of gastroesophageal reflux disease.
Pace F; Pace M
Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):423-7. PubMed ID: 20678016
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitors in the management of gastroesophageal reflux disease.
Hrelja N; Zerem E
Med Arh; 2011; 65(1):52-5. PubMed ID: 21534455
[TBL] [Abstract][Full Text] [Related]
6. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
Azzam RS
Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
[TBL] [Abstract][Full Text] [Related]
7. Impaired Mucosal Integrity in Proximal Esophagus Is Involved in Development of Proton Pump Inhibitor-Refractory Nonerosive Reflux Disease.
Norita K; Asanuma K; Koike T; Okata T; Fujiya T; Abe Y; Nakagawa K; Hatta W; Uno K; Nakamura T; Nakaya N; Asano N; Imatani A; Shimosegawa T; Masamune A
Digestion; 2021; 102(3):404-414. PubMed ID: 32784296
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and Treatment of Patients with Persistent Reflux Symptoms Despite Proton Pump Inhibitor Treatment.
Spechler SJ
Gastroenterol Clin North Am; 2020 Sep; 49(3):437-450. PubMed ID: 32718563
[TBL] [Abstract][Full Text] [Related]
9. Evolving issues in the management of reflux disease?
Yuan Y; Hunt RH
Curr Opin Gastroenterol; 2009 Jul; 25(4):342-51. PubMed ID: 19417644
[TBL] [Abstract][Full Text] [Related]
10. Results of short-and long-term medical treatment of gastroesophageal reflux disease (GERD).
Pohle T; Domschke W
Langenbecks Arch Surg; 2000 Aug; 385(5):317-23. PubMed ID: 11026702
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of proton pump inhibitors in nonerosive reflux disease.
Dean BB; Gano AD; Knight K; Ofman JJ; Fass R
Clin Gastroenterol Hepatol; 2004 Aug; 2(8):656-64. PubMed ID: 15290657
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
[TBL] [Abstract][Full Text] [Related]
13. [Management of gastroesophageal reflux disease (GERD) with refractory to standard dose of proton pump inhibitor].
Iwakiri K; Kawami N; Tanaka Y; Sano H; Kotoyori M; Sakamoto C
Nihon Rinsho; 2007 May; 65(5):913-20. PubMed ID: 17511233
[TBL] [Abstract][Full Text] [Related]
14. Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis.
Shirai Y; Kawami N; Iwakiri K; Kuwana M
J Scleroderma Relat Disord; 2022 Feb; 7(1):57-61. PubMed ID: 35386943
[TBL] [Abstract][Full Text] [Related]
15. Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.
Gyawali CP
Curr Gastroenterol Rep; 2017 Sep; 19(9):46. PubMed ID: 28780717
[TBL] [Abstract][Full Text] [Related]
16. pH, healing rate, and symptom relief in patients with GERD.
Huang JQ; Hunt RH
Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
[TBL] [Abstract][Full Text] [Related]
17. Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis.
Iwakiri K
J Nippon Med Sch; 2017; 84(5):209-214. PubMed ID: 29142181
[TBL] [Abstract][Full Text] [Related]
18. [Pathogenesis of GERD--peculiarity of NERD].
Kinoshita Y; Furuta K; Adachi K
Nihon Rinsho; 2007 May; 65(5):822-8. PubMed ID: 17511219
[TBL] [Abstract][Full Text] [Related]
19. Demographic, clinical, and psychological characteristics of the heartburn groups classified using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal reflux disease group.
Lee KJ; Kwon HC; Cheong JY; Cho SW
Digestion; 2009; 79(3):131-6. PubMed ID: 19307735
[TBL] [Abstract][Full Text] [Related]
20. Maintenance therapy of gastroesophageal reflux disease.
Nagahara A; Hojo M; Asaoka D; Watanabe S
Clin J Gastroenterol; 2010 Apr; 3(2):61-8. PubMed ID: 26189996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
